Tavapadon

AbbVie's phase three TEMPO-1 trial showed significant improvements in early-stage Parkinson’s disease with tavapadon, a D1/D5 dopamine receptor partial agonist, compared to placebo. Both 5 mg and 15 mg doses led to reduced MDS-UPDRS scores, indicating better motor function. Side effects were mild to moderate, consistent with previous trials. The TEMPO program includes additional trials to assess tavapadon's efficacy and safety.

AbbVie's Phase 3 TEMPO-1 trial for tavapadon met primary and secondary endpoints, showing significant improvement in MDS-UPDRS Parts II and III scores at week 26. Results from TEMPO-2 trial expected by end of 2024.

Tavapadon, an AbbVie drug for early Parkinson’s disease, met phase 3 TEMPO-1 trial goals, improving motor skills in 529 participants. The trial showed significant improvements with 5 mg and 15 mg doses compared to placebo, with mild to moderate adverse events. Tavapadon also improved symptom control as an add-on to levodopa in another trial, with results from a flexible-dose monotherapy trial expected by year-end.

Tavapadon, a dopamine agonist, met its primary endpoint in the TEMPO-1 trial for Parkinson’s disease, showing significant reduction in MDS-UPDRS scores. This follows positive results from the TEMPO-3 trial, with the final TEMPO-2 trial expected to conclude this year. Tavapadon aims to offer effective treatment with minimal side effects.

AbbVie announces positive Phase 3 TEMPO-1 trial results for tavapadon, a D1/D5 dopamine receptor partial agonist, as a monotherapy for early Parkinson's disease, showing significant reduction in MDS-UPDRS Parts II and III scores compared to placebo.

2024 sees ongoing FTC scrutiny of life sciences transactions, including Novo's $16.5B Catalent acquisition and AbbVie's $8.7B Cerevel deal. The FTC challenges 'junk' patents in the FDA's Orange Book and releases an interim report on PBMs. The EU Commission opens its first abuse-of-dominance probe related to Zoetis shelving a veterinary therapy. Despite regulatory focus, deals in radiopharmaceuticals and metabolic diseases proceed without notable investigations.

Darigabat (CVL-865) targets GABA-A receptor subunits for panic disorder and drug-resistant focal onset seizures, with an expected revenue of $112 mn by 2036 in the US. Cerevel Therapeutics, developing Darigabat, reported operating and net losses of $447.3 mn and $432.8 mn in FY2023, respectively. The risk-adjusted NPV (rNPV) model, available for purchase, provides a conservative valuation by accounting for drug development risks.

AbbVie to acquire Cerevel Therapeutics for $8.7B, enhancing its neuroscience pipeline. FDA approves Novartis' Fabhalta for PNH and Lilly's Jaypirca for second leukemia indication. Pfizer halts phase III for danuglipron due to side effects. J&J forecasts sales growth, Roche to buy Carmot Therapeutics for obesity treatments.

AbbVie acquires Cerevel Therapeutics for $8.7B, enhancing its neuroscience pipeline with drugs targeting schizophrenia, Parkinson’s, and dementia. The deal, 22% above Cerevel's stock price, reflects growing pharma interest in neuroscience. Cerevel's advanced Parkinson’s drug, tavapadon, and schizophrenia therapy, emraclidine, highlight the acquisition's potential.